Peter Divanach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Divanach has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Anastassia N. Rissanou
Institute of Theoretical and Physical Chemistry, National Hellenic Research Foundation, 48 Vassileos Konstantinou Ave, Athens 11635, Greece
1 shared publication - Anna Mitraki
Department of Materials Science and Engineering, University of Crete, Voutes Campus, 70013 Heraklion, Greece
1 shared publication - Antzela Noti
Department of Materials Science and Engineering, University of Crete, Voutes Campus, GR-70013 Heraklion, Greece
1 shared publication - Nikos Kountourakis
Proteomics Facility, Institute of Molecular Biology & Biotechnology, Foundation for Research and Technology-Hellas (FORTH), Nikolaou Plastira 100, GR-70013 Heraklion, Greece
1 shared publication - Panagiotis Vouvopoulos
Department of Materials Science and Engineering, University of Crete, Voutes Campus, GR-70013 Heraklion, Greece
1 shared publication - Thanasis Athanasiou
Institute of Electronic Structure and Laser, FORTH 1 , Heraklion 70013
1 shared publication
Latest Publications
- Open Access
- 8 June 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (6) , 839
FmocFF Peptide Hydrogel Is a Promising Matrix for Encapsulation and Controlled Release of the Anticancer Peptide Drug Bortezomib
One major public health issue is cancer chemotherapy; despite constant progress in the area, administration of anticancer drugs to patients is often associated with serious side effects. It is therefore imperative to develop vehicles for encapsulation and controlled delivery of such drugs. Anticancer drugs include small peptide drugs, such as Bortezomib (BTZ). Self-assembling peptides have been recently reported as promising drug delivery agents. The research reported here proposes the encapsulation of BTZ into peptide hydrogels formed by the self-assembling FmocFF dipeptide as delivery vehicle. We selected FmocFF as an encapsulation vehicle based on our previous simulation study on the complexation propensity of Bortezomib (BTZ) with various peptide gelators. Herein we undertook additional computational studies that highlight the benefits of FmocFF as a potential effective nanocarrier for BTZ combined with experiments of encapsulation and evaluation of BTZ release. Based on these computational and experimental results, we propose the Fmoc-FF dipeptide hydrogel as a promising matrix for the controlled delivery of BTZ.
- 8 June 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (6) , 839
Open AccessFmocFF Peptide Hydrogel Is a Promising Matrix for Encapsulation and Controlled Release of the Anticancer Peptide Drug Bortezomib
One major public health issue is cancer chemotherapy; despite constant progress in the area, administration of anticancer drugs to patients is often associated with serious side effects. It is therefore imperative to develop vehicles for encapsulation and controlled delivery of such drugs. Anticancer drugs include small peptide drugs, such as Bortezomib (BTZ). Self-assembling peptides have been recently reported as promising drug delivery agents. The research reported here proposes the encapsulation of BTZ into peptide hydrogels formed by the self-assembling FmocFF dipeptide as delivery vehicle. We selected FmocFF as an encapsulation vehicle based on our previous simulation study on the complexation propensity of Bortezomib (BTZ) with various peptide gelators. Herein we undertook additional computational studies that highlight the benefits of FmocFF as a potential effective nanocarrier for BTZ combined with experiments of encapsulation and evaluation of BTZ release. Based on these computational and experimental results, we propose the Fmoc-FF dipeptide hydrogel as a promising matrix for the controlled delivery of BTZ.